Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Novel Insights of Illness Evolution And Mortality Risk Profiles for the Non-Survivors with COVID-19
25 Pages Posted: 8 Apr 2020
More...Abstract
Background: The outbreak of COVID-19 has attracted the attention of the whole world. Our study aims to describe illness evolution and mortality risk profiles for non-survivors.
Methods: We retrospectively analyzed 155 patients with COVID-19 in Wuhan and focused on eighteen non-survivors among them. We compared the dynamic profile of laboratory data from hospital admission date to death date of the patients. The survival curve was analyzed by Kaplan-Meier.
Findings: Of the non-survivors, the median age was 73·5 years old and the proportion of males was 72·2%. Fifteen individuals had chronic medical illnesses. Five and thirteen patients were hospital-acquired and community-acquired infections, respectively. Five were co-infected with other pathogens. The interval between disease onset and diagnosis was 8·5 days (IQR, [4-11]). With the deterioration of the disease, most patients gradually developed lymphopenia, increased WBC and neutrophil counts, decreased platelet count, decreased total plasma protein and albumin, as well as elevated D-dimer. Notably, procalcitonin were dynamically increased from their admission date to death date. These patients exhibited decreased CD3+T, CD3+CD4+Th, and CD3+CD8+Tc cell count in the peripheral blood. All patients died within 45 days after hospitalization, with the median survivor time of 13·5 days (IQR, 8-17).
Interpretation: We drew a clear picture of disease progression in non-survivors. Our data showed biochemical and immune parameters dynamically changed during illness evolution in non-survivors, suggesting the importance of early intervention.
Funding Statement: The study was supported by the Key Project for Anti-2019 novel Coronavirus Pneumonia from the Ministry of Science and Technology, China (no. 2020YFC0845500).
Declaration of Interests: We declare no competing interests.
Ethics Approval Statement: This study was conducted according to the principles of Helsinki and approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (No.2020063). Due to the urgent need for this emerging epidemic, the requirements for informed consent from patients were waived.
Keywords: COVID-19, non-survivor, clinical course, co-infection, mortality, immune dysfunction
Suggested Citation: Suggested Citation